October 1, 2024
BURLINGTON, Ontario – October 1, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that as contemplated in the secured convertible notes (the “Notes”) previously issued on its private placement financing (the “Financing”), the Company intends to issue common shares...
September 16, 2024
BURLINGTON, Ontario – September 14, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that further to its press release dated August 7, 2024, regarding a proposed equity private placement financing (the “Financing”), the Company has received an extension from...
August 26, 2024
BURLINGTON, Ontario – August 6, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that it has appointed Jason Lewis as a director of the Company, effective immediately. Mr. Lewis is Senior Vice President, Business Development, of RDT and was...
July 22, 2024
BURLINGTON, Ontario – July 18, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that it has closed a first tranche of its previously announced equity private placement financing (the “Financing”) for aggregate gross proceeds of $309,000. The...
July 2, 2024
BURLINGTON, Ontario – July 2, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that as contemplated in the secured convertible notes (the “Notes”) previously issued on its private placement financing (the “Financing”), the Company intends to issue common shares...
July 2, 2024
Burlington, Ontario – June 28, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), is pleased to announce the filing of its financial results for the year ended February 29, 2024. Mark Upsdell, Chairman and Chief Executive Officer, stated, “Over the past...
June 25, 2024
Burlington, Ontario – June 25, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) trading on the Canadian Securities Exchange (“CSE”) under the symbol DOSE is pleased to announce the recent award of a Mitacs Accelerate grant, with a value of $30,000 in May...
June 19, 2024
BURLINGTON, Ontario – June 17, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that further to its press release dated May 8, 2024, regarding a proposed equity private placement financing (the “Financing”), the Company has received an extension from...
May 29, 2024
BURLINGTON, Ontario – May 29, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announces its collaboration in the National Football League (NFL) – funded clinical trial program entitled “Naturally Produced Cannabinoids for Pain Management and Neuroprotection from Concussion and Participation in...
May 22, 2024
Burlington, Ontario – May 22, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) trading on the Canadian Securities Exchange (“CSE”) under the symbol DOSE in partnership with McMaster University (“McMaster”) is pleased to announce the publication of the results of their collaborative research...